Regeneron Reports Q3 Sales of $3.72 Billion, Eylea Combined Net Sales $1.54 Billion, Stock Drops 9%

Regeneron Pharmaceuticals reported weaker-than-expected quarterly sales for its high-dose version of the eye disease drug Eylea, resulting in a 9% decline in its stock. The company announced total revenues of $3.72 billion for Q3 2024, an 11% year-over-year increase, with combined net sales for Eylea HD and Eylea reaching $1.54 billion. Despite this growth, the performance of Eylea HD has not significantly impacted the market momentum of Roche's competing drug, Vabysmo. As competition from biosimilars looms, investor confidence appears to be wavering, raising concerns about Regeneron's market position.